drugset / Trial / NCT02459119
Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477)
Phase 2
Completed
17 enrolled
University of Alabama at Birmingham
Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma · collab
NaSingle-groupOpen-labelTreatment
Summary
This study will test how well Regorafenib controls disease progression in urothelial cancer (cancer occurring in the urinary bladder, ureters, or renal pelvis) following previous therapy with chemotherapy.
Timeline
- Start
- 2015-05
- Primary completion
- 2019-02
- Completion
- 2020-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Regorafenib | Small molecule | 160 mg | Oral |